Table of Contents

State/Territory Name: Utah

State Plan Amendment (SPA) #: UT-14-008

This file contains the following documents in the order listed:

- 1) Approval Letter
- 2) 179
- 3) Approved SPA Pages

TN: UT-14-008 Approval Date: 1/24/14 Effective Date: 1/1/14

DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Medicare & Medicaid Services 7500 Security Boulevard, Mail Stop S2-14-26 Baltimore, Maryland 21244-1850



Disabled & Elderly Health Programs Group

January 24, 2014

W. David Patton, Ph.D. Executive Director Utah Department of Health P.O. Box 143102 Salt Lake City, UT 84114-3102

Dear Dr. Patton:

We have reviewed the Utah State Plan Amendment (SPA) 14-008 received in the Denver Regional Office on December 31, 2013. The State of Utah proposes to remove the drug categories of barbiturates, benzodiazepines and smoking cessation drugs from the list of drugs that may be excluded or restricted from coverage from the state plan effective January 1, 2014, in accordance with the provisions of section 2502 of the Affordable Care Act amends section 1927(d)(2) of the Social Security Act (the Act) by removing barbiturates, benzodiazepines, and agents used to promote smoking cessation from the list of drugs a state Medicaid program may exclude from coverage or otherwise restrict. Based on the information provided, we are pleased to inform you that SPA 14-008 is approved with an effective date of January 1, 2014.

A copy of the CMS-179 form as well as the pages approved for incorporation into the state plan will be forwarded by the Denver Regional Office. If you have any questions regarding this amendment, please contact Madlyn Kruh at (410) 786-3239.

Sincerely,

/ s /

Kimberly Howell Acting Director Division of Pharmacy

cc: Richard C. Allen, ARA, Denver Regional Office Sonia Hinojosa, Denver Regional Office Craig Devashrayee, Utah Department of Health

DEPARTMENT OF HEALTH AND HUMAN SERVICES HEALTHCARE FINANCING ADMINISTRATION		FORM APPROVED OMB NO. 0938-0193
TRANSMITTAL AND NOTICE OF APPROVAL OF STATE PLAN MATERIAL	1. TRANSMITTAL NUMBER: 14-008-UT	2. STATE: Utah
FOR: HEALTH CARE FINANCING ADMINISTRATION	3. PROGRAM IDENTIFICATION: TITLE XIX OF THE SOCIAL SECURITY ACT (MEDICAID)	
TO: REGIONAL ADMINISTRATOR HEALTHCARE FINANCING ADMINISTRATION DEPARTMENT OF HEALTH AND HUMAN SERVICES	4. PROPOSED EFFECTIVE DATE January 1, 2014	
5. TYPE OF PLAN MATERIAL (Check One)		
	TO BE CONSIDERED AS NEW PLA	
COMPLETE BLOCKS 6 THRU 10 IF THIS IS	AN AMENDMENT (Separate Transr	nittai for each amendment)
6. FEDERAL STATUTE/REGULATION CITATION:	7. FEDERAL BUDGET IMPACT: a. FFY 2014 \$[156,700] b. FFY 2015 \$[208,900]	
42 CFR 440.120		
8. PAGE NUMBER OF THE PLAN SECTION OR ATTACHMENT:	PAGE NUMBER OF THE SUPERSEDED PLAN SECTION OR ATTACHMENT (If Applicable)	
Page 1a of Attachment #12a within ATTACHMENTS 3.1-A tnd 3.1-B	Page 1a of Attachment #12a within ATTACHMENTS 3.1 and 3.1-B	
11. GOVERNOR'S REVIEW (Check One): GOVERNOR'S OFFICE REPORTED NO COMMENT COMMENTS OF GOVERNOR'S OFFICE ENCLOSED	OTHER, AS SPEC	CIFIED:
NO REPLY RECEIVED WITHIN 45 DAYS OF SUBMITT		
12. SIGNATURE OF STATE AGENCY OFFICIAL:	16. RETURN TO:	
13. TYPED NAMÉ: W. David Patton, Ph.D.	Craig Devashrayee, Manager Technical Writing Unit Utah Department of Heath PO Box 143102 Salt Lake City, UT 84114-3102	
14. TITLE: Executive Director, Utah Department of Health		
15. DATE SUBMITTED: December 17, 2013		
16		
17. DATE RECEIVED	18 DATE APPROVED: January 24, 2014	
	NALUSE ONLY	SKEUPIKI.
19. EFFECTIVE DATE OF APPROVED MAYERIAL January 1, 2014	20. SIGNATURE OF REGIONAL	N. E. B. G. W.
21 TYPED NAME: Richard C. Allen	22 TITLE ARA, DMCHO	
The state of the s		

PLAN APPROVED - ONE COPY ATTACHED

25 REMARKS

PRESCRIBED DRUG SERVICES

LIMITATIONS

- 3. Drug Efficacy Study Implementation Project Drugs (DESI Drugs) as determined by the FDA to be less-than-effective are not a benefit of the Medicaid program.
- 4. Other drugs and/or categories of drugs as determined by the Utah State Division of Health Care Financing and listed in the Pharmacy Provider Manual are not a benefit of the Medicaid program.
- 5. In accordance with Utah Law 58-17b-606(4), when a multi-source legend drug is available in the generic form, reimbursement for the generic form of the drug will be made unless the treating physician demonstrates a medical necessity for dispensing the non-generic, brand-name legend drug. However, the Department of Health pharmacists may override the generic mandate provisions if a financial benefit will accrue to the state (See Utah Code 58-17b-606(5)).
- 6. The Division shall implement a preferred drug list for selected therapeutic drug classes beginning August 1, 2007. The therapeutic classes will be selected and a preferred drug or drugs for each therapeutic class implemented at the discretion of the Division.

T.N. # ______ Approval Date 01/24/14

Supersedes T.N. # 13-001 Effective Date 1-1-14

PRESCRIBED DRUG SERVICES

LIMITATIONS

- 3. Drug Efficacy Study Implementation Project Drugs (DESI Drugs) as determined by the FDA to be less-than-effective are not a benefit of the Medicaid program.
- 4. Other drugs and/or categories of drugs as determined by the Utah State Division of Health Care Financing and listed in the Pharmacy Provider Manual are not a benefit of the Medicaid program.
- 5. In accordance with Utah Law 58-17b-606(4), when a multi-source legend drug is available in the generic form, reimbursement for the generic form of the drug will be made unless the treating physician demonstrates a medical necessity for dispensing the non-generic, brand-name legend drug. However, the Department of Health pharmacists may override the generic mandate provisions if a financial benefit will accrue to the state (See Utah Code 58-17b-606(5)).
- 6. The Division shall implement a preferred drug list for selected therapeutic drug classes beginning August 1, 2007. The therapeutic classes will be selected and a preferred drug or drugs for each therapeutic class implemented at the discretion of the Division.